A detailed history of Group One Trading, L.P. transactions in Ocugen, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 424,926 shares of OCGN stock, worth $390,931. This represents 0.02% of its overall portfolio holdings.

Number of Shares
424,926
Previous 651,381 34.77%
Holding current value
$390,931
Previous $1.01 Million 58.37%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.98 - $1.95 $221,925 - $441,587
-226,455 Reduced 34.77%
424,926 $420,000
Q2 2024

Aug 14, 2024

BUY
$1.18 - $1.98 $31,370 - $52,638
26,585 Added 4.25%
651,381 $1.01 Million
Q1 2024

May 10, 2024

BUY
$0.5 - $1.83 $61,372 - $224,623
122,745 Added 24.45%
624,796 $1.02 Million
Q4 2023

Feb 14, 2024

BUY
$0.36 - $0.57 $121,290 - $192,043
336,918 Added 204.03%
502,051 $286,000
Q3 2023

Nov 09, 2023

BUY
$0.4 - $0.62 $17,537 - $27,183
43,844 Added 36.15%
165,133 $66,000
Q2 2023

Aug 09, 2023

SELL
$0.45 - $0.88 $5,768 - $11,279
-12,818 Reduced 9.56%
121,289 $65,000
Q1 2023

May 12, 2023

BUY
$0.82 - $1.33 $3,371 - $5,467
4,111 Added 3.16%
134,107 $113,000
Q4 2022

Feb 09, 2023

BUY
$1.11 - $1.87 $92,319 - $155,529
83,171 Added 177.62%
129,996 $168,000
Q3 2022

Nov 09, 2022

SELL
$1.75 - $3.1 $268,450 - $475,540
-153,400 Reduced 76.61%
46,825 $83,000
Q2 2022

Aug 11, 2022

BUY
$1.83 - $3.45 $256,018 - $482,658
139,901 Added 231.92%
200,225 $455,000
Q1 2022

May 12, 2022

SELL
$2.34 - $4.72 $77,699 - $156,727
-33,205 Reduced 35.5%
60,324 $199,000
Q4 2021

Feb 11, 2022

BUY
$4.38 - $15.67 $409,657 - $1.47 Million
93,529 New
93,529 $426,000

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $199M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.